BFC Planning’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
Other funds holding CRNX
BFC Planning's CRNX Position: Q3 2026 in Review
BFC Planning sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2026, closing a stake of 79 shares — an estimated $2.96K sold.
BFC Planning first reported a position in CRNX in Q3 2024 and held it in 7 quarters. The position peaked at $2.96K in Q2 2026. 2 funds tracked by Wall St. Rank hold CRNX as of Q3 2026.
- BFC Planning reported no remaining Crinetics Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- BFC Planning sold 79 Crinetics Pharmaceuticals shares in Q3 2026, an estimated $2.96K.
- BFC Planning first reported a position in Crinetics Pharmaceuticals in Q3 2024 and held it in 7 quarters.
- BFC Planning's Crinetics Pharmaceuticals position peaked at $2.96K in Q2 2026.
- 2 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.